Altheia Science

Executive Summary

Altheia Science is an Italian biotechnology company headquartered in Milan, founded in 2018. The company is focused on developing innovative cell and gene therapies aimed at providing curative treatments for patients with autoimmune diseases. Leveraging advanced technologies, Altheia Science seeks to address significant unmet medical needs in the autoimmune space, where current treatments often provide symptomatic relief rather than durable remission. The company operates in the rapidly evolving fields of RNA and gene therapy, as well as cell and gene therapy, positioning itself at the forefront of precision medicine. As a private entity with limited public information, Altheia Science appears to be in early-stage development, with no disclosed pipeline assets, funding history, or partnerships. The company's potential lies in its novel approach to autoimmunity, but its success will depend on advancing candidates into preclinical and clinical stages.

Upcoming Catalysts (preview)

• TBDSeries A funding round60% success
• TBDPreclinical proof-of-concept data for lead candidate40% success
• TBDAcademic or industry partnership announcement35% success